Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
174
-
Total 13F shares, excl. options
-
68.6M
-
Shares change
-
+6.57M
-
Total reported value, excl. options
-
$255M
-
Value change
-
+$21.7M
-
Put/Call ratio
-
0.78
-
Number of buys
-
80
-
Number of sells
-
-69
-
Price
-
$3.72
Significant Holders of ImmunityBio, Inc. - COM (IBRX) as of Q3 2024
226 filings reported holding IBRX - ImmunityBio, Inc. - COM as of Q3 2024.
ImmunityBio, Inc. - COM (IBRX) has 174 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.6M shares
.
Largest 10 shareholders include VANGUARD GROUP INC (16.9M shares), BlackRock, Inc. (11.9M shares), STATE STREET CORP (8.65M shares), GEODE CAPITAL MANAGEMENT, LLC (3.85M shares), MORGAN STANLEY (2.25M shares), BANK OF AMERICA CORP /DE/ (2.07M shares), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.54M shares), GOLDMAN SACHS GROUP INC (1.29M shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (1.27M shares), and NORTHERN TRUST CORP (1.23M shares).
This table shows the top 174 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.